CFM
ACRS icon

Catalyst Funds Management’s Aclaris Therapeutics ACRS Stock Holding History

Catalyst Funds Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,698
Closed -$25.5K – 432
2025
Q1 		$25.5K Buy
16,698
+2,698
+19% +$5.75K 0.01% 435
2024
Q4 		$34.7K Hold
14,000
– – 0.01% 285
2024
Q3 		$16.1K Hold
14,000
– – ﹤0.01% 1115
2024
Q2 		$15.4K Buy
+14,000
New +$16.5K ﹤0.01% 771

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Catalyst Funds Management's ACRS Position: Q2 2025 in Review

Catalyst Funds Management sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 16,698 shares — an estimated $25.5K sold.

Catalyst Funds Management first reported a position in ACRS in Q2 2024 and held it in 4 quarters. The position peaked at $34.7K in Q4 2024. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Catalyst Funds Management reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 16,698 Aclaris Therapeutics shares in Q2 2025, an estimated $25.5K.
  • Catalyst Funds Management first reported a position in Aclaris Therapeutics in Q2 2024 and held it in 4 quarters.
  • Catalyst Funds Management's Aclaris Therapeutics position peaked at $34.7K in Q4 2024.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Catalyst Funds Management's 13F filing for Q2 2025, filed 12 Aug 2025.